Indian court rejects AstraZeneca’s injunction request

The Delhi High Court has refused to grant AstraZeneca an injunction against the manufacture and sale of dapagliflozin by a group of India-based pharmaceutical companies.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

India regulator U-turns on controversial generics-only policy

31 August 2023 National Medical Commission has put new regulations on hold that would have made prescribing generics mandatory | Move comes after pressure from doctors’ organisation and pharma firms.

Generics

AstraZeneca loses major generics appeal in India

22 July 2021 The Delhi High Court has cleared the way for a slew of generic diabetes drugs to arrive on the Indian market after it rejected AstraZeneca’s request for a blocking order.

Americas

AstraZeneca to buy Alexion for $39bn

14 December 2020 AstraZeneca has announced it will acquire Boston-based biopharmaceutical company Alexion Pharmaceuticals, in what is potentially the biggest life sciences deal of this year.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

Indian court rejects AstraZeneca’s injunction request

More on this story

Editor's picks

Editor's picks

More features